Registration Strip Icon for monitor 브라질 증권 거래소, NASDAQ, NYSE, AMEX, LSE 등 주요 거래소에서의 다양한 실시간 주식 시세를 모니터링합니다.

ROIVW

Roivant Sciences (ROIVW)

Roivant Sciences Ltd
일자:
정렬 기준:
 검색 관련기사 보기:NASDAQ:ROIVW
일자시간출처헤드라인심볼기업
2024/05/3020:00GlobeNewswire Inc.Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provides Business UpdateNASDAQ:ROIVWRoivant Sciences Ltd
2024/05/1705:05GlobeNewswire Inc.Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provide Business Update on Thursday, May 30, 2024NASDAQ:ROIVWRoivant Sciences Ltd
2024/04/0220:00GlobeNewswire Inc.Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 MillionNASDAQ:ROIVWRoivant Sciences Ltd
2024/02/1321:00GlobeNewswire Inc.Roivant Reports Financial Results for the Third Quarter Ended December 31, 2023, and Provides Business UpdateNASDAQ:ROIVWRoivant Sciences Ltd
2024/01/3106:05GlobeNewswire Inc.Roivant to Report Financial Results for the Third Quarter Ended December 31, 2023, and Provide Business Update on Tuesday, February 13, 2024NASDAQ:ROIVWRoivant Sciences Ltd
2023/12/2106:30GlobeNewswire Inc.Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ DiseaseNASDAQ:ROIVWRoivant Sciences Ltd
2023/12/1423:00GlobeNewswire Inc.Roche Completes Acquisition of Telavant from Roivant, Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel DiseaseNASDAQ:ROIVWRoivant Sciences Ltd
2023/11/2821:00GlobeNewswire Inc.Roivant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class PotentialNASDAQ:ROIVWRoivant Sciences Ltd
2023/11/2722:00GlobeNewswire Inc.Roivant and Priovant Announce Results from Phase 2 Study of Oral Brepocitinib in Systemic Lupus ErythematosusNASDAQ:ROIVWRoivant Sciences Ltd
2023/11/1321:00GlobeNewswire Inc.Roivant Reports Financial Results for the Second Quarter Ended September 30, 2023, and Provides Business UpdateNASDAQ:ROIVWRoivant Sciences Ltd
2023/11/1022:00GlobeNewswire Inc.Roivant Announces Appointment of Mayukh Sukhatme to Its Board of DirectorsNASDAQ:ROIVWRoivant Sciences Ltd
2023/10/3106:30GlobeNewswire Inc.Roivant to Report Financial Results for the Second Quarter Ended September 30, 2023, and Provide Business Update on Monday, November 13, 2023NASDAQ:ROIVWRoivant Sciences Ltd
2023/10/2314:00GlobeNewswire Inc.Roche Enters Into a Definitive Agreement to Acquire Telavant Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease From RoivantNASDAQ:ROIVWRoivant Sciences Ltd
2023/09/2619:00GlobeNewswire Inc.Roivant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD ResultsNASDAQ:ROIVWRoivant Sciences Ltd
2023/09/1121:00GlobeNewswire Inc.Roivant Announces Completion of Redemption of its Outstanding WarrantsNASDAQ:ROIVWRoivant Sciences Ltd
2023/08/1805:05GlobeNewswire Inc.Roivant Announces Redemption Fair Market Value in Connection with Redemption of its Outstanding WarrantsNASDAQ:ROIVWRoivant Sciences Ltd
2023/08/1420:00GlobeNewswire Inc.Roivant Reports Financial Results for the First Quarter Ended June 30, 2023, and Provides Business UpdateNASDAQ:ROIVWRoivant Sciences Ltd
2023/08/0405:05GlobeNewswire Inc.Roivant to Report Financial Results for the Quarter Ended June 30, 2023, and Provide Business Update on Monday, August 14, 2023NASDAQ:ROIVWRoivant Sciences Ltd
2023/08/0305:05GlobeNewswire Inc.Roivant Announces Redemption of Outstanding WarrantsNASDAQ:ROIVWRoivant Sciences Ltd
2023/07/2721:00GlobeNewswire Inc.Telavant, a Roivant Company, Advances Inflammatory Bowel Disease Program with First Patient Dosed in Global Phase 2 Trial of Novel Anti-TL1A Antibody RVT-3101 in Crohn’s DiseaseNASDAQ:ROIVWRoivant Sciences Ltd
2023/07/1412:06KR Market News로이반트, 로슈에 $70억 가치의 장 치료제 판매 협상 중NASDAQ:ROIVWRoivant Sciences Ltd
2023/07/1121:00GlobeNewswire Inc.Roivant Ranks No. 25 on Fast Company’s Fifth Annual List of the 100 Best Workplaces for Innovators and is the Winner on the Science and Technology List as a Part of the Best Workplaces for Innovators ProgramNASDAQ:ROIVWRoivant Sciences Ltd
2023/06/2821:57GlobeNewswire Inc.UPDATE -- Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023, and Provides Business UpdateNASDAQ:ROIVWRoivant Sciences Ltd
2023/06/2820:00GlobeNewswire Inc.Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023, and Provides Business UpdateNASDAQ:ROIVWRoivant Sciences Ltd
2023/06/2705:05GlobeNewswire Inc.Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023, and Provide Business Update on Wednesday, June 28, 2023NASDAQ:ROIVWRoivant Sciences Ltd
2023/06/2220:30GlobeNewswire Inc.Roivant Reports Chronic Period Data for RVT-3101 from the TUSCANY-2 Phase 2b Study in Ulcerative Colitis, Demonstrating Improved Efficacy from the Induction to Chronic PeriodNASDAQ:ROIVWRoivant Sciences Ltd
2023/06/2206:00GlobeNewswire Inc.Roivant to Host Investor Call at 8:00 AM ET on Thursday, June 22 to Review Results from the Chronic Period of TUSCANY-2, a Large Global Phase 2b Study of RVT-3101 (Anti-TL1A Antibody) in Ulcerative ColitisNASDAQ:ROIVWRoivant Sciences Ltd
2023/05/1620:00GlobeNewswire Inc.Roivant Reports Positive Topline Results from ADORING 1, the Second Atopic Dermatitis Phase 3 Trial of VTAMA® (tapinarof) Cream, 1% in Adults and Children as Young as 2 Years OldNASDAQ:ROIVWRoivant Sciences Ltd
2023/03/2821:00GlobeNewswire Inc.Covant and Boehringer Ingelheim Collaborate to Develop a Novel ADAR1 Inhibitor for Use in Cancer PatientsNASDAQ:ROIVWRoivant Sciences Ltd
2023/03/1520:45GlobeNewswire Inc.Roivant Reports Positive Topline Results from ADORING 2 Atopic Dermatitis Phase 3 Trial of VTAMA® (tapinarof) Cream, 1% Once Daily in Adults and Children as Young as 2 Years OldNASDAQ:ROIVWRoivant Sciences Ltd
 검색 관련기사 보기:NASDAQ:ROIVW

최근 히스토리

Delayed Upgrade Clock